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INVESTIGATING THE ROLE OF PRMT1 AND ARGININE METHYLATION OF HSP70 
IN HUMAN PANCREATIC CANCER 
Liang Wang B.S. 
Advisory Professor: Keping Xie, M.D., Ph.D. 
Protein arginine methyltransferase 1 (PRMT1) is the major arginine methyltransferase, 
which catalyzes the addition of one or two methyl groups to the arginine residues of its 
substrate proteins. The best known substrate for PRMT1 is histone, while more and more 
non-histone proteins are now found to be methylated by PRMT1. Dysregulation of PRMT1 
is reported in several human cancer types. However, its biological roles in human 
pancreatic cancer initiation and development are still unclear. In the first part of this study, 
I found that the expression level of PRMT1 was elevated in both human and mouse 
pancreatic cancer tissues in immunohistochemistry analysis. The further functional 
studies demonstrated a pro-tumorigenic role of PRMT1 in several pancreatic cancer cell 
lines and mouse models.  
In the second part of this study, several heat shock protein 70 (HSP70) family members 
were found to interact with PRMT1 in co-immunoprecipitation assays. Furthermore, using 
in vitro methylation assay and mass spectrometry analysis, I revealed that HSP70 was a 
novel methylation substrate of PRMT1, and two conserved arginine residues were 
identified as the methylation sites. By using HSP70 knockout cells generated by CRISPR/ 
Cas9 system and a series of wildtype and methylation sites mutant HSP70 expression 
vectors, I demonstrated that PRMT1-mediated arginine methylation was essential for the 
drug resistance function of HSP70 in pancreatic cancer cells. 
Collectively, my results not only elucidate the important role of PRMT1 in pancreatic 
cancer pathogenesis, but also suggest a novel underlying mechanism of HSP70-mediated 
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drug resistance to chemotherapeutic agents. Therefore, targeting PRMT1-HSP70 axis 
could be a new therapeutic regimen for pancreatic cancer. 
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CHAPTER 1 BACKGROUND 
1.1 PANCREATIC CANCER 
The pancreas is a glandular organ belonging to both digestive system and endocrine 
system in human beings. It is located deep in the abdominal cavity and behind the 
stomach. The pancreas has two major functions that are performed by two functionally 
differentiated cell compartments. The exocrine part of pancreas, which consists of ductal 
and acinar cells and is about 80-90% of this organ, is responsible for producing pancreatic 
juice containing many digestive enzymes. These enzymes help to break down and absorb 
nutrient macromolecules in the small intestine. The endocrine part of pancreas is often 
called pancreatic islets, and is about 10-20% of this organ. The islets secrete several 
important hormones, such as insulin, glucagon, somatostatin, and pancreatic polypeptide, 
into the blood circulation to regulate the blood glucose level and maintain a proper 
metabolism within the body. 
Pancreatic cancers have several subtypes and may occur in either exocrine or endocrine 
part of pancreas, but the former one, which is the typical pancreatic adenocarcinoma, is 
the most common form, and accounts for about 85% of all pancreatic cancer cases (1). 
The pancreatic endocrine tumors make up for less than 5% of all cases. Pancreatic cancer 
accounts for more than 200,000 deaths every year worldwide (2). In the United States, 
pancreatic cancer is now surpassing breast cancer and is the third leading cause of 
cancer-related death in the year 2016 (3). Moreover, it is expected to become the second 
leading cause of cancer-related death in the US by the year 2030, surpassing colorectal 
cancer (4). 
Although the causes of pancreatic cancer are still insufficiently known, some risk factors 
have been identified. Age is the most important predictor of pancreatic cancer. The median 
age of diagnosis is 71 years and almost all patients are older than 45 years (1). Smoking, 
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diabetes mellitus, chronic pancreatitis, and obesity are known risk factors associated with 
pancreatic cancer (1). Consumption of red or processed meat, fat, and alcohol is also 
associated with increased risk while vegetarian diet is associated with decreased risk of 
pancreatic cancer (5). 
It is estimated that 5 to10 percent of pancreatic cancers are hereditary, but the precise 
genetic basis for familial aggregation has not been determined in most cases (6). Some 
established genetic disorders and affected genes that are known to increase the risk for 
pancreatic cancer include hereditary pancreatitis (PRSS1, SPINK1), familial atypical 
multiple mole and melanoma syndrome (CDKN2A), hereditary breast and ovarian cancer 
syndromes (BRCA1, BRCA2, PALB2), Peutz-Jeghers syndrome (STK11), hereditary 
nonpolyposis colon cancer (Lynch syndrome) (MLH1, MSH2, MSH6), Li-Fraumeni 
syndrome (P53), etc. (1, 7, 8). Although screening patients with an inherited predisposition 
for pancreatic cancer is of great value, there is currently no reliable screening methods to 
screen and detect pancreatic cancer early (5).  
Because of the non-specificity and late appearance of symptom, most pancreatic cancer 
patients are diagnosed at advanced stages, which make them unsuitable for surgical 
resection of tumor tissues (5). According to an NCI cancer statistics review, the five-year 
survival rate in the US is around 8%, and median survival for pancreatic cancer patients 
is only 6 months (9). The dismal prognosis of pancreatic cancer is largely due to its late 
diagnosis, early metastasis, and resistance to conventional chemotherapy and 
radiotherapy. 
Pancreatic ductal adenocarcinoma (PDAC) is by far the most common pancreatic cancer 
type. It is an invasive mucin-producing gland-forming neoplasm, and features of a very 
high rate of activating mutations in KRAS (>90%) and an extensive stromal reaction, which 
is termed desmoplasia (1). PDAC arises from non-invasive precursor lesions that are 
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microscopic non-invasive epithelial proliferations within the pancreatic ducts. The most 
prevalent type of such precursor lesions is named pancreatic intraepithelial neoplasias 
(PanINs)(1). Based on the architectural and cytological atypia, PanINs are categorized 
into low-grade PanIN1, intermediate-grade PanIN2, and high-grade PanIN3 dysplasia 
(1).  Molecular pathology studies and genomic analyses have established a model of 
stepwise progression of PanIN from low grade to high grade and finally to invasive PDAC. 
During the long progression time of this disease (in human beings it can be 10 to 20 years), 
various genetic alternations accumulate at different stages. There are four major gene 
mutations, one oncogene and three tumor suppressor genes, that are usually regarded 
as driver mutations in PDAC (10). KRAS gene encodes a small GTPase that mediates 
multiple downstream signaling pathways from growth factor receptors, including PI3K-
AKT pathway and Raf-MEK-ERK pathway. Activating mutation (most commonly codon 12 
and 13) of KRAS renders its GTPase activity constitutively active, and is the most frequent 
and first somatic mutation that can be detected in PDAC progression (10). It occurs in 
about 40% of low-grade PanIN1 lesions and more than 90% in high-grade PanIN2 or 3 
and PDACs. CDKN2A (also known as cyclin-dependent kinase Inhibitor 2A), which 
encodes an essential cell-cycle arrest regulator, is mutated in a loss-of-function way at 
relatively early PanIN stages (10). In PDAC, its mutation rate is more than 50%. By 
contrast, somatic mutations in TP53 and SMAD4 tumor suppressor genes often occur in 
PanIN3 and invasive carcinoma (10). Aberrant expression of p53 mutant proteins impairs 
multiple cellular stress responses, such as DNA damage repair and cellular senescence, 
while loss-of-function mutation of SAMD4 disrupts normal TGF-β signaling pathway (10). 
All these mutations further promote cancer progression to the advanced stage and/or 
tumor metastasis. 
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Besides PanIN, some PDACs arise from macroscopic cystic precursors—namely, 
intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms 
(MCNs), although these two types are far less common than PanIN (2). IPMNs and MCNs 
are also categorized into low-grade, intermediate-grade, and high-grade dysplasia based 
on the degree of dysplasia in the lining epithelium, but the genetic alternations occurring 
in these precursor lesions are not the same as PanINs. For example, mutations in the 
oncogenic GNAS gene occur only in IPMNs, whereas inactivating mutations in the 
ubiquitin ligase RNF43 occur in both IPMNs and MCNs (11, 12).  
In addition to PDAC, there are some other types of pancreatic tumors that belong to 
pancreatic exocrine tumor, such as acinar cell carcinoma, pancreatoblastoma, solid-
pseudopapillary carcinoma, serious cystadenocarcinoma, intraductal papillary-mucinous 
tumor, mucinous cystadenoma, osteoclast-like giant cell tumor, miscellanceous 
carcinoma and so on (10). Pancreatic cancer derived from endocrine cells are less than 5 
percent of all primary pancreatic tumors, and most of the pancreatic endocrine tumors 
occur in aged people. It mainly includes insulinoma, small cell carcinoma, glucagonoma, 
gastrinoma and so on (13). Non-epithelial tumors have two types, soft tissue tumor and 
lymphoma. This dissertation studied the molecular mechanisms of biology and 
pathogenesis of pancreatic ductal adenocarcinoma, and potential therapeutics for this 
disease. Thus the term pancreatic cancer in this dissertation is referred to pancreatic 
ductal adenocarcinoma without specific explanation after this point. 
To date, the clinical available treatments for pancreatic cancer are still very limited. 
Surgical resection is the only way that can cure this disease and significantly increase 
survival time compared with other treatment options, but only 15-20% of pancreatic cancer 
cases are resectable at the time of diagnosis (1). Chemotherapy is the mainstay of 
treatment for locally advanced and metastatic pancreatic cancer. Gemcitabine, a 
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nucleoside analog, is the only widely accepted first-line chemotherapeutic agent for 
pancreatic cancer in the past two decades (2). However, a high degree of intrinsic and 
acquired resistance to gemcitabine is often observed in clinical practice, which limits the 
efficiency of this chemotherapy (14).  From a mechanistic perspective, gemcitabine 
resistance may result from alterations in genes/proteins involved in drug transportation 
and metabolism, or from the influences of cancer microenvironment. To understand, 
monitor and overcome the drug resistance against gemcitabine will benefit pancreatic 
cancer patients profoundly. 
Two recent clinical trials compared combination chemotherapy over single-agent 
gemcitabine to treat pancreatic cancer. In these studies, combined use of fluorouracil, 
irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX), or gemcitabine plus albumin bound 
paclitaxel particles (nab-paclitaxel), improved the survival and quality of life of patients 
with metastatic pancreatic cancer (15, 16).  Results from these studies may provide new 
directions for pancreatic cancer chemotherapy in the future. Mutant KRAS targeting drug 
has been a hot study focus for decades. However, due to the undrugable nature of mutant 
KRAS protein, small molecule drug targeting mutant KRAS are still not available in clinical 
use. To bypass the KRAS obstacle, researchers put many efforts on investigation of other 
types of alterations involved in pancreatic cancer pathogenesis, including epigenetic, 
transcriptional, and proteomic alterations. Among them, the post-translational modification 
(PTM) of vital proteins is believed to be an important way to control protein expression 
and/or functions in a highly dynamic mode to help tumor cells adapt to and survive the 
harsh microenvironment. The studies on PTM regulation will not only expand our 
knowledge on tumor initiation and progression, but may also reveal additional targets for 
novel approaches in cancer diagnosis and therapy. 
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1.2 PROTEIN ARGININE METHYLATION AND PROTEIN ARGININE 
METHYLTRSNFERASE 
Post-translational modification is the process to add one or more chemical groups to a 
protein after its translation. Common types of PTMs are phosphorylation, acetylation, 
ubiquitination and methylation, etc. By attaching and removing different chemical groups 
to and from specific amino acid residues in a protein, the three dimensional conformation, 
positive or negative charges, hydrophilic or hydrophobic property of this protein is quickly 
changed, and subsequently, the protein stability, subcellular localization and/or its 
interacting molecules are altered correspondingly. PTMs give cells, particularly cancer 
cells, the ability to quickly and efficiently regulate the functions of some vital proteins to 
help them deal with the ever-changing external and internal microenvironments. 
Protein methylation is the process that one or more methyl groups are added to the 
nitrogen side chains in the arginine and/or lysine residues of proteins by S-adenosyl-
methionine (SAM) dependent methyltransferases. Arginine is unique among the amino 
acids as its guanidino group contains five potential hydrogen bond donors that are 
positioned for favorable interactions with biological hydrogen bond acceptors (17). Each 
methyl group added to an arginine residue of a protein not only changes its conformation, 
but also removes a potential hydrogen bond donor, which may change the interacting 
repertoire of this protein and therefore affect its physiological functions. For example, 
arginine methylation of the Sam68 proline-rich motifs can inhibit its binding to SH3, but not 
WW domains (18).  Importantly, methylation does not neutralize the cationic charge of an 
arginine residue (19). 
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There are three types of arginine methylation that can be found in mammalian cells: 
ω-NG-monomethylarginine (MMA), ω-NG,NG-asymmetric dimethylarginine (ADMA) and 
ω-NG,N’G-symmetric dimethylarginine (SDMA) (Fig.1)(17). The formation of MMA, ADMA 
and SDMA in mammalian cells is carried out by a sequence-related family of nine protein 
arginine methyltransferases (PRMTs)(17)(Table 1). Each PRMT species harbors the 
characteristic motifs of seven beta strand methyltransferases (20), and all PRMTs can 
catalyze MMA formation. Additionally, Type I PRMTs (PRMT1, PRMT2, PRMT3, 
PRMT4/CARM1, PRMT6 and PRMT8) can further catalyze ADMA formation, in which the 
second methyl group is added to the same guanidino nitrogen atom, while Type II PRMTs 
(PRMT5 and PRMT9) can add the second methyl group to the other guanidino nitrogen 
atom of the arginine, resulting in an SDMA (17). Particularly, PRMT7 is the only Type III 
enzyme, exclusively catalyzing the formation of MMA (21, 22). Most of the PRMTs are 
ubiquitously expressed, except for PRMT8, which is reported to be predominantly 
expressed in the brain (23).  
Most PRMTs methylate glycine- and arginine-rich (GAR) motifs in their substrate proteins. 
Indeed, PRMT1, PRMT3, PRMT6 and PRMT8 mainly recognize and methylate RG or 
RGG repeats in GAR motifs, but they do not seem to be functionally redundant in vivo, 
because cells knock-down or -out of these enzymes display different abnormalities, and 
differential proteins are hypomethylated in those cells (17). Some PRMTs have their own 
substrate specificity. For example, PRMT4/CARM1 preferentially modifies arginine 
residues present in proline-, glycine-, and methionine-rich (PGM) regions rather than GAR 
motifs. PRMT5 modifies substrates containing both GAR and PGM motifs, while  
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PRMT7 preferentially modifies substrates with an RXR motif, consisting a pair of arginine 
residues separated by one basic residue (21). One thing should be emphasized is that the 
preferential motif for PRMTs is not a stringent rule, because many PRMT substrates have 
been found that they do not contain these typical motifs (24, 25). As a result of arginine 
methylation, GAR and PGM methylated motifs interact mainly with proteins via their Tudor 
domains (26). The human genome encodes over thirty members of these proteins, such 
as human survival motor neuron protein, splicing factor 30 (SPF30) and Tudor domain-
containing proteins (TDRD) subfamily, which are functionally involved in many cellular 
processes (27). 
PRMT1 and PRMT5 are the major asymmetric and symmetric arginine 
methyltransferases, respectively, and knockout either of these enzymes leads to early 
embryonic lethality in mouse models (28, 29). Other PRMTs have fewer substrates and 
have evolved more specialized cellular localization and/or functions. The aberrant 
expression of PRMTs and the dysregulation of their enzymatic activity have been 
associated with many diseases, including neurodegenerative diseases and several types 
of cancer (30, 31). Insights into distinct roles of different PRMTs are anticipated to provide 
new approaches for cancer prevention, diagnosis and treatment. 
PRMT1 is the first mammalian PRMT identified as a single gene product, and is the 
primary PRMT that its activity accounts for more than 90% of the methylarginine residues 
in mammalian cells (32). PRMT1 has a very wide substrate specificity, and proteins 
localized in cell nucleus, cytoplasm and membrane can be methylated by PRMT1. 
Upregulation of this protein is observed in many types of human cancers, including breast, 
prostate, lung, colon, bladder cancer and leukemia (30). The best studied substrate for 
PRMT1 is histone. Methylation of arginine residues in histone tails is a part of the “histone 
code”, which is believed to be an important process of epigenetic regulation. Arginine 3 of 
11 
 
histone 4 (H4R3) is the primary site that PRMT1 specifically deposits an ADMA, which is 
a marker for transcription activation (30). In prostate cancer, the status of H4R3 
methylation correlates with higher tumor grade and can be used to predict the risk of 
cancer recurrence (33). ZEB1 is a key transcription factor inducing the epithelial-
mesenchymal transition (EMT) by repressing the transcription of E-cadherin. H4R3 
methylation at the ZEB1 promoter activates its transcription and thereby promotes 
migration and invasion of breast cancer (34). 
A large number of non-histone PRMT1 substrates that involved in multiple cellular 
processes have also been identified. BRCA1 has tumor suppressor activity in cell cycle 
regulation, DNA damage repair and chromatin remodeling. It was found to be methylated 
by PRMT1 in both breast cancer cell lines and tumor specimens (35). This methylation 
changes recruitment of BRCA1 to specific gene promoters, and dysregulation of BRCA1 
methylation could result in genomic instability. Moreover, PRMT1 methylates the DNA 
repair pathway proteins MRE11 and p53 binding protein 1 (53BP1) (36, 37). Aberrant 
methylation of these proteins disrupts their proper localization to damaged DNA and 
prevents the recruitment of DNA repair machinery, which leads to an accumulation of DNA 
damage. PRMT1 also methylates some proteins that are involved in cell signaling 
transduction. For instance, in estrogen signaling, the estrogen receptor α (ERα) is 
methylated by PRMT1 at arginine 260 (R260) in the DNA binding domain, and estrogen 
treatment of MCF7 cells rapidly increases R260 methylation (38).  This modification 
promotes the formation of a protein complex consisting of methylated ERα/Src/ PI3K, and 
the subsequent activation of AKT pathway. High level expression of methylated ERα and 
this protein complex is also an independent marker of poor prognosis of breast cancer 
(39, 40). 
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PRMT1-mediated methylation is found to crosstalk with other PTMs adjacent to the 
methylated arginine residues. One such example is that methylation of the Forkhead box 
O1 (FOXO1) transcription factor, on R248 and R252 residues in an AKT consensus 
phosphorylation motif, can block AKT-mediated phosphorylation on adjacent S253 
residue, and therefore prevent FOXO1 proteasomal degradation and increase its nuclear 
localization and transcriptional activity on its targeting genes (41). Likewise, a crosstalk 
between PRMT1-mediated methylation and AKT-mediated phosphorylation is observed 
in the BCL-2 antagonist of cell death (BAD) protein, and affects BAD function in apoptosis 
regulation (42). 
1.3 HEAT SHOCK PROTEINS AND CANCER 
Heat shock protein (HSP) is a large group of proteins involved in protein folding and 
maturation. Their expression is induced by heat shock or other environmental stimuli. 
Traditionally, HSPs are also known as molecular chaperones due to their physiological 
and protective roles in cells. They facilitate protein folding in protein synthesis and 
maturation process, and prevent aggregation of proteins when cells are exposed to 
environmental challenges, such as high temperature, hypoxia, heavy metals toxicity, 
reactive oxygen species (ROS), drugs, or other chemical agents that may induce cell 
stress or protein denaturation (43). HSPs are usually classified based on their molecular 
weights and include HSP27, HSP40, HSP60, HSP70, HSP90, and large HSPs (HSP110 
and glucose-regulated protein 170, GRP170). Except for the group of small HSPs, like 
HSP27, HSP proteins have ATPase activity, and their molecular chaperone function is 
ATP-dependent. Heat shock factors (HSFs) are transcription factors that can bind to the 
heat shock elements (HSEs) upstream of HSP genes to induce the expression of HSPs 
when cells are exposed to various stresses (44).  
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HSPs are highly conserved proteins that they are found in virtually all living organisms, 
from bacteria to humans, which substantiate their important roles in life. During long time 
of evolution, HSPs evolved into many functionally related proteins, but their tissue 
specificity, subcellular localization and the stresses they deal with are distinct from each 
other. In this dissertation, the function and post-translational modification of HSP70, as 
well as some other members in this family, are studied. Therefore, some background 
knowledge of HSP70 protein family is introduced in this section. 
The HSP70 family is encoded by the HSPA gene family and consists of 13 members in 
mammals (45). HSP70 proteins have a highly conserved domain structure, including the 
44 kDa N-terminal nucleotide-binding domain (NBD), which has ATPase activity, the 18 
kDa substrate-binding domain (SBD), and the 10 kDa C-terminal lid domain. When the 
NBD domain is ADP- or ATP-bound, the lid domain is in a closed or open conformation, 
which facilitate the binding or release of client proteins (46). HSP70 chaperone activity is 
regulated by some co-chaperones, such as HSP40, Bcl-2-associated athanogene 1 (BAG-
1), and C terminus of HSP70-interacting protein (CHIP) (43). 
There are five important members in HSP70 family that are well-studied and shown to be 
associated with cancer (43). The HSP70 (also known as HSPA1 or HSP72, ~72 kDa) and 
HSP70B’ (also known as HSPA6, ~71 KDa) are stress-inducible protein chaperons, while 
HSC70 (also known as HSPA8, ~73 kDa), GRP75 (also known as HSPA9 or mortalin, ~75 
kDa), and GRP78 (also known as HSPA5 or BIP, ~78 kDa) are constitutively expressed 
in cells. HSP70, HSP70B’ and HSC70 are mainly localized in the cytosol, while GRP75 
and GRP78 are mainly localized in mitochondria and endoplasmic reticulum (ER), 
respectively. All these HSP70 proteins have crucial functions in facilitating protein folding, 
maintaining the natural conformation of their client proteins, and promoting cell survival 
following diverse stresses. The role and dysregulation of these proteins in cancer 
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development is a hot topic in cancer research and has been reported by several studies 
(43, 47).  
HSP70 is reported to be overexpressed in multiple tumor types, including colon, liver, 
prostate, esophagus and cervix. Later on, the prognostic significance of HSP70 has be 
proved in several human cancers, and it is independent on other prognostic factors (48). 
Although HSP70 is overexpressed in most human cancers, lower expression of HSP70 is 
observed in certain cancers, such as renal cancer (49). Therefore, by now HSP70 has not 
been accepted as a clinical biomarker of any cancer parameter.  
Observations that many types of tumors have elevated levels of HSP70 indicate that 
HSP70 may have a pro-survival function in tumor cells. Since tumor cells live under 
conditions of continuous stress, such as hypoxia, nutrient deprivation, low pH and/or ROS, 
survival and development of tumor require adaptations that overcome stress-induced 
apoptosis. Indeed, HSP70 was discovered to suppress apoptosis by inhibiting both 
intrinsic and extrinsic apoptotic pathways (47). Besides, HSP70 was also showed to be 
able to inhibit oncogene-induced senescence and stabilizes lysosome membrane that 
allows for autophagy (47). Because of these functions, HSP70 is required by tumor cells 
rather than normal cells for their survival and growth. Moreover, mutant HSP70 protein 
lacking chaperone function still retained their ability to protect cells from tumor necrosis 
factor (TNF)-induced apoptosis, indicating a non-chaperone function of HSP70 in cell 
biology (50). 
HSP70 protein promotes tumorigenesis and it is also involved in mediating drug resistance 
in cancer therapy. For example, overexpression of HSP70 in fibrosarcoma WEHI-S 
cells increased their resistance against gemcitabine and topotecan (51). Knockdown of 
HSP70 enhanced the sensitivity to cisplatin in cervical cancer cells (52). Overexpression 
of HSP70 promoted bortezomib resistance, while inhibition of HSP70 enhanced 
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bortezomib-induced cell death in human bladder cancer cells (53). Given its important 
roles in cancer biology, HSP70 protein is a promising drug target that many drugs targeting 
this protein are under investigation either as monotherapy or as combined therapy with 
other chemo drugs. These drugs interrupt HSP70 functions via different mechanisms, 
such as blocking HSF1-dependent transcription of HSP70, decreasing ATPase activity of 
HSP70, disrupting the interaction of HSP70 with its co-chaperon BAG3, and so on (43).  
Other members in HSP70 family are also reported to have cancer related functions. For 
example, HSC70 can bind to the non-phosphorylated tumor-suppressor retinoblastoma 
(Rb) protein and to mutant forms of p53 and p73 to inhibit their degradation (54); GRP75 
is involved in myeloid malignancies and is commonly deleted in patients with acute 
myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (55); GRP78 is 
responsible for maintaining normal ER functions and prevent ER stress-induced apoptosis 
in cancer cells (56). GRP75 and GRP78 can also mediate drug resistance in cancer 
therapy, and they are reported be potential therapeutic targets for anticancer drugs (43). 
Inhibiting the expression and/or function of these proteins by siRNA, antibodies, natural 
compound or small molecule drugs can alleviate drug resistance in certain cancer cells 
(43). 
Since most HSP70 proteins are stress-induced and elevated expressions of some 
members are observed in cancers, the regulation of HSP70 proteins was studied in the 
past two decades. Transcriptional regulation is the best known mechanism used by cells 
to increase HSPs under environmental stress. HSF-1 is considered to be the main heat 
shock factors (HSFs) that are responsible for transcriptional activation of HSPA genes. 
Under normal conditions, HSF-1 is retained by HSP70 and HSP90 in the cytoplasm as an 
inactive monomer. In response to stress, HSF-1 is released and a HSF-1 homotrimer is 
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formed that it binds to the heat shock elements (HSEs) upstream of HSPA promoters, 
thereby triggering HSPA gene transcription (57). 
Apart from transcriptional regulation, HSP70 protein levels have also been found to be 
regulated at the post-transcriptional level either by micro-RNAs (miRNAs) or a recently 
identified mRNA post-transcriptional modification, N(6)-methyladenosine (58). 
Under heat shock condition, certain adenosines within the 5'UTR region of newly 
transcribed HSP70 mRNA are preferentially methylated to form N (6)-methyladenosine. 
This modification enables cap-independent mRNA translation initiation to rapidly increase 
HSP70 protein level within cells under heat shock condition (58). 
Compared with above mentioned regulation of HSP70, little is known about the post-
translational processing of HSP70 proteins. Although some amino acid residues are found 
to be phosphorylated, acetylated, malonylated or methylated, how they affect HSP70 
protein function remains unclear (59). Phosphorylation of Ser400 of HSP70 is critical for 
the nuclear distribution of this chaperone (60). Methylation was first found to occur on a 
conserved lysine residue (K561) of HSP70, and the lysine trimethylation altered the affinity 
of this chaperone to its client protein, α-synuclein (61). During my dissertation work, the 
first arginine methylation of HSP70 was reported that CARM1/PRMT4-mediated 
monomethylation of arginine 469 regulated HSP70 function in RARβ2 gene activation 
(62). Since HSP70 is a highly dynamic protein and post-translational modification is an 
energy-efficient and quick way to modulate protein trafficking, function and/or its 
interactions with other partners, this dissertation will focus on the study of post-
translational modification, mainly arginine methylation, of HSP70 protein.  
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CHAPTER 2 DEFINITIVE ROLE OF PRMT1 IN PANCREATIC CANCER 
PATHOGENESIS 
2.1 INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies. 
Although some driver oncogenes, like KRAS, have been identified and characterized, the 
molecular mechanisms underlying PDAC carcinogenesis, particularly the early initiation 
stage, are still not well understood. Moreover, given that PDAC is less sensitive to the 
conventional chemotherapy and KRAS is believed to be undrugable, the discovery of 
novel molecular targets for PDAC prevention and/or intervention is urgently needed.  
As it is outlined in Chapter 1, protein arginine methylation, as one of the common post-
translational modifications (PTMs), plays important roles in many biological processes, 
such as gene transcription regulation, RNA processing, signal transduction and protein 
trafficking, etc., and aberrant expression of some PRMTs are associated with many 
human cancers (30). However, since methyl group is the smallest chemical group, of 
which the molecular mass is only 14, that can be added to a protein, and its addition does 
not change the electric charge of the protein, protein methylation is more difficult to detect 
and study when compared with other PTMs, like phosphorylation. Therefore, protein 
arginine methylation is generally less studied except for histone methylation. Before the 
beginning of my dissertation study, the expression and activity of PRMTs and the protein 
arginine methylation status in PDAC have not been reported yet. Some studies showing 
the functions of PRMTs in other cancer types prompt us to study the roles of PRMTs in 
PDAC pathogenesis. 
In this chapter, the expression pattern of some PRMTs, primarily PRMT1, in both human 
and mouse pancreatic cancer specimens was studied by immunohistochemical (IHC) 
staining. The relationship between its expression and some clinicopathologic parameters 
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was analyzed using a human pancreatic cancer tissue microarray. The effects of loss-of-
function, either by siRNA or small molecule inhibitors, and gain-of-function of PRMT1 on 
cancer cell growth, migration and invasion in vitro, and tumor growth in vivo were studied. 
My study reveals that PRMT1 has tumor promoting function and it is a protein biomarker 
of poor prognosis for pancreatic cancer patients. Inhibition of PRMT1 expression or 
methyltransferase enzymatic activity can decrease tumor growth in vitro and in vivo.  
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2.2 MATERIAL AND METHODS 
Plasmids, siRNAs, antibodies and compounds 
Full-length PRMT1 transcript variant 1 plasmid was purchased from OriGene 
Technologies, and the ORF was subcloned into a pCMV6-AC-HA-His vector backbone 
with C-terminal HA-His tag. siRNA specifically targeting PRMT1 was purchased from 
Santa Cruze or synthesized by Sigma-Aldrich Corporate, with the sequence 5’- 
GCCAACAAGUUAGACCACG-3’.  Cell transfection was performed with Lipofectamine 
2000 transfection reagent according to manufacturer’s suggestion (Thermo Fisher 
Scientific, Waltham, MA). Anti-PRMT1 (2449S) antibody was purchased from Cell 
Signaling Technology; anti-PRMT5 (07-405) antibody was purchased from EMD Millipore 
Corporation; and anti-HA (TA100012) antibody was purchased from OriGene 
Technologies. PRMT1 specific inhibitors DB75 and TC-E5003 were purchased from 
Tocris Bioscience.  
Human and mouse tissue specimens and immunohistochemical staining 
Tissue microarray (TMA) or sections (5 μm thick) of formalin-fixed, paraffin-embedded 
human or mouse normal and tumor tissue specimens were prepared and processed for 
immunohistochemistry to detect various protein expressions using corresponding 
antibodies. Tissue slides were immersed in Dako target retrieval solution (Dako North 
America, Carpinteria, CA) and heated in a steamer for 30 minutes. Cool down slides to 
room temperature, and endogenous peroxidase was deactivated using 3% hydrogen 
peroxide in PBS for 10 min. All tissue specimens were covered by blocking solution, which 
is PBS (pH 7.4) containing 5% normal donkey serum and bovine serum albumin, and 
incubated for 30 minutes at room temperature. Tissue specimens were covered by primary 
antibodies (1:150-1:400 dilution in 5% BSA solution), and incubated overnight at 4°C. The 
samples were then rinsed by PBS for 3×5 minutes and incubated for 1 hour at room 
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temperature with Horseradish Peroxidase (HRP) conjugated secondary antibodies. Next, 
the slides were rinsed by PBS for 3×5 minutes and incubated with diaminobenzidine (DAB) 
for 2 to 10 minutes. The slides were washed three times with distilled water, 
counterstained with Harris hematoxylin (Fisher Scientific, Kalamazoo, MI), and washed in 
running tab water for 2 minutes. Finally, the slides were mounted using Permount 
Mounting Medium (Biomeda Corporation, Foster City, CA) and examined or photographed 
using a bright-field Leica microscope. 
A positive signal was indicated by a reddish-brown color staining. The percentage of 
positive signal area was scored as (percentage scores) : <10% (0), 10–25% (1), 25–50% 
(2), 50–75% (3), and >75% (4). The intensity of staining was scored as (intensity scores): 
no staining (0), light brown (1), brown (2), and dark brown (3). The overall score is obtained 
by multiplying percentage score and intensity score. The overall score <4 is regarded as 
negative/weak expression, 4 ≤ overall score < 8 is regarded as moderate expression and 
overall score ≥ 8 is regarded as strong expression. For each mouse sample, five or six 
randomly selected fields were scored and calculated to get the average staining score. All 
tissues sections were scored by 2 independent investigators prior not knowing the patient 
outcomes, and the mean values of 2 independent scores are presented. 
Cell line information and cell culture conditions 
All human pancreatic adenocarcinoma cell lines and human embryonic kidney cell line 
293T were purchased from the American Type Culture Collection (Manassas, VA) if it is 
not specified otherwise. FG human pancreatic adenocarcinoma cells were established by 
Vezeridis et al (63).  Human pancreatic stellate cells (HPSC) were kindly provided 
by Rosa Hwang (64). All of the cell lines were maintained in plastic flasks in 37°C 5% CO2 
incubators as adherent monolayer in high glucose Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential 
21 
 
amino acids, L-glutamine, penicillin/streptomycin and a vitamin solution (Flow 
Laboratories, Rockville, MD).  
Animal information and animal care 
Female athymic nude mice and C57BL/6 mice were purchased from Jackson Laboratory 
(Bar Harbor, ME). The Pdx1-Cre; LSL-KrasG12D mice have been described previously (65). 
All mice were housed in laminar flow cabinets under specific pathogen-free conditions and 
were used when they were 8 weeks old. The animals were maintained in in MD Anderson 
Cancer Center animal facility approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care in accordance with the current regulations and 
standards of the U.S. Department of Agriculture, Department of Health and Human 
Services, and National Institutes of Health.  
Western blot analysis 
Cells were harvested at ~80 to 95% confluence and lysed with cell lysis buffer. Protein 
concentrations were measured using the Bradford Protein assay (Bio-Rad Laboratories). 
Lysates were boiled in LDS sample buffer (Thermo Fisher Scientific Inc.) for 10 minutes 
and cooled on ice for 5 minutes. Protein samples were separated in 10% SDS-PAGE gels 
for 2h in electrophoresis buffer (25 mmol/L Tris-HCl (pH 8.3), 192 mmol/L glycine, 0.1% 
SDS) and then electrophoretically transferred onto nitrocellulose membranes in transfer 
buffer (25 mmol/L Tris-HCl, 192 mmol/L glycine, 20% methanol) for 2 hour at 250 mA. The 
membranes were incubated in blocking buffer (5% nonfat milk in PBST) for 1 hour at room 
temperature with shaking and then rinsed twice briefly with PBST (PBS containing 0.1% 
Tween-20). The membranes were then incubated with primary antibodies diluted 1:1000 
in %5 BSA solution at 4ºC overnight.  Then the membrane was washed three times with 
PBST and incubated with secondary antibodies (anti-rabbit or -mouse immunoglobulin, 
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horseradish peroxidase–linked F(ab)2 fragment) diluted 1:2,000 in %5 BSA solution for 1 
hour at room temperature with shaking. Targeting proteins were detected using enhanced 
chemiluminescence (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
instructions. 
Boyden chamber invasion assay 
Invasion chambers containing Matrigel-coated polyethylene terephthalate membranes 
with 8μm pores were purchased from BD Bio-Sciences in a 24-well plate format. 
Pancreatic cancer cells (3×105) in a 300-μL volume of serum-free medium were seeded 
in the upper compartments of invasion chambers. Ten percent fetal bovine serum medium 
was placed in the lower compartments as a chemoattractant, and invasion assays were 
carried out for 48 hours at 37ºC. Each cell line or condition was tested in triplicate. To 
examine cell invasion, after 48 hour incubation, cells on the upper surface of the 
membrane were removed, and the cells invaded to the lower surface were fixed and 
stained with hematoxylin and eosin. Membranes were removed from the chambers, 
washed to remove excessive dye, and mounted on glass slides with lower surface facing 
up. Photos were taken under microscopy at 200x magnification and cell numbers were 
counted in 5 independent fields. Relative invasive activity was measured by calculating 
ratios of experimental cell numbers to control cell numbers. 
Scratch wound healing assay 
Cells transfected with PRMT1 expression plasmid, pcDNA3.1 control plasmid or PRMT1 
siRNA and control scramble siRNA were seeded in six-well plates until confluence. A 
wound was generated on the cell monolayer by scraping with a 10-μL pipette tip. Twelve 
hours later, the cells on the wounded monolayer were photographed, and cell migration 
was assessed by measuring wound sizes in multiple fields. There were no significantly 
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changes in cell numbers among those groups within 12h as were determined under a 
microscope in ten randomly selected fields at a magnification of 200×. Thus the impact of 
cell proliferation on “wound closing” ability was minimized within that time period. 
Subcutaneous xenograft experiments 
Tumor cells (1×106) in 0.1 mL of Hank’s balanced salt solution (HBSS) without calcium 
and magnesium were injected subcutaneously into the flanks of nude mice. The tumors’ 
length and width were measured with a caliper twice a week. The tumor-bearing mice 
were sacrificed when they became moribund or on indicated time points after inoculation, 
and the tumors were removed and weighed. The tumor volumes (mm3) were calculated 
using the formula: width2 × length / 2. The administration of PRMT1 inhibitor, DB75, was 
intraperitoneal injected to the mice twice every week for three weeks. The low dose was 
5mg/kg and high dose was 20mg/kg. Vehicle solution was used as control. 
In vitro drug cytotoxicity assay 
Human PDAC cells were seeded in 96-well plates with 3,000 cells per well. PRMT1 
inhibitors (DB75 and TC-E5003) were diluted in DMEM medium supplemented with 2% 
FBS. 200μl Medium with drug concentration ranging from 10-7 to 10-4 M or vehicle control 
were added to each well, and cells were cultured at 37°C for 72h. After incubation, cell 
viability was determined using Cell Counting Kit-8 (CCK-8, Dojindo Molecular 
Technologies, Rockville, MD, USA), and IC50 for each drug was calculated using Prism 
GraphPad 6 software. The viability of vehicle control group was determined as 100%, and 
each drug concentration was tested in triplicate. 
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Statistics. 
Kaplan-Meier survival curves were calculated using the overall survival time for each 
human patient. The log-rank test was used to test the significant differences between 
groups. For image quantification and staining score analysis, statistical significance was 
assayed by Student's t-test with Prism GraphPad software (two-tailed unpaired or paired t-
test depending on the experiment—variance was first systematically examined using an F-
test). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns: not significant. Data are represented as 
mean ± SD or mean ± s.e.m. 
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2.3 RESULTS 
2.3.1 PRMT1 is overexpressed in human PDAC cell lines and tumor tissues. 
There are nine PRMT members (PRMT1-9) encoded in mammalian genome, and they 
can catalyze the formation of three types of arginine methylation. Among nine PRMTs, 
PRMT1 and PRMT5 are the primary asymmetric (Type I) and symmetric (Type II) arginine 
methyltransferases, respectively. Thus the expression of these two proteins were first 
studied in human pancreatic cancer cell lines and colon tumor sections available in our 
laboratory (Fig.2). It is found that the expression levels of PRMT1 in a panel of PDAC cell 
lines were very different, from high expression, like FG, L3.7 and MDA 28 cells, to low 
expression, like AsPC-1, Capan-2 and MDA 48 cells (Fig.2A). In general, PRMT1 was 
highly expressed in PDAC cell lines when compared with immortalized human pancreatic 
duct cell line, HPNE. It is interesting to find that PRMT1 was moderately expressed in 
HPDE cells, which were generated by transduction of HPV16-E6, E7 genes (66). Thus the 
p53 and pRb pathways are inactivated in HPDE cell line. Whether this could be a reason 
for moderate PRMT1 expression awaits further study. In contrast to PRMT1, the 
expression level of PRMT5 is relatively homogeneous among all tested cell lines (Fig. 2A).  
Consistent with the cell line data, the immunohistochemistry (IHC) staining results of 
human colon tumor sections also revealed that PRMT1 was overexpressed in tumor cells 
when compared with adjacent normal cells. The tumor cells showed stronger nuclear 
staining of PRMT1 than normal glandular epithelial cells (Fig.2C). However, there is no 
dramatic difference between the staining of PRMT5 in tumor and normal cells (Fig.2B). 
Based on these observations, I postulated that aberrant expression of PRMT1 was 
associated with cancer pathogenesis, and my following study would focus on the role of 
PRMT1 in carcinogenesis. 
26 
 
 
 
 
 
  
27 
 
Table 2. Clinicopathologic parameters and PRMT1 expression of the pancreatic 
cancer patients 
Variable  Total No.  PRMT1   P value 
 High    Low 
 
Age (n=76)        0.670 
<60        35   12 23 
≥60        41   16 25 
Gender(n=77)       0.367 
Male        50   20 30 
Female       27   8 19 
pT(n=76)        0.543 
T1        4   1 3 
T2        60   24 36 
T3        12   3 9 
pN(n=77)        0.310 
N0        47   15 32 
N1        30   13 17 
pM(n=77)        0.129 
M0        75   26 49 
M1        2   2 0 
Histological Grade 
(n=77)         0.029 * 
1        7   3 4 
2        45   11 34 
3        25   14 11 
pTMN(n=76)        0.164 
I        36   12 24     
II        38   14 24 
III        0   0 0 
IV        2   2 0 
        * A result is statistically significant when calculated p value is less than 0.05. 
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A human pancreatic cancer tissue microarray containing 90 paired tumor tissues and 
adjacent normal tissues was used to study the expression pattern of PRMT1. The patient 
information can be found in Table 2. In summary, elevated expression of PRMT1 was 
observed in tumor tissues than adjacent normal tissues, and PRMT1 was mainly 
expressed in the cell nucleus (Fig. 3A, B and C). High expression of PRMT1 was 
associated with shorter overall survival time of patients and poorer differentiation status of 
tumor tissues (Fig. 3D, Fig. 4 and Table 2). 
To further validate the reactivity of PRMT1 antibody and generalize our observation in 
pancreatic cancer, human colon cancer and gastric cancer tissues were also IHC stained 
for PRMT1. Similarly, PRMT1 protein is overexpressed in tumor cells than adjacent normal 
epithelial cells, and it is mainly localized in cell nucleus (Fig. 5). 
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2.3.2 PRMT1 protein expression is gradually elevated during PDAC development in 
mouse models. 
Since most human pancreatic cancer cases are diagnosed at relative late stages, it is 
difficult to observe pre-cancerous lesions, such as PanINs, in human patient pancreatic 
cancer specimens. Mutant KRAS-induced mouse pancreatic cancer model is widely used 
in preclinical researches, and these models recapitulate the step-wise development of 
pancreatic cancer seen in humans (67). The mouse line kept in our laboratory is the LSL-
KrasG12D/+; Pdx-Cre model (also known as KC model). During mouse embryonic 
development, Cre recombinase is specifically expressed under the control of PDX 
promoter in all pancreatic cells that are derived from pan-pancreatic progenitor cells, and 
therefore KrasG12D is activated in mouse pancreas. By 8 weeks of age, the mice begin to 
develop early PanIN (PanIN 1A/B) lesions that slowly increase in both number and grade 
over the next 2 years. After a long progression time, usually > 8 months, a subset of these 
mice develop PDAC, with a median overall survival of 14 months (67). This mouse model 
gives us opportunities to observe pre-cancerous development at the initiation stage of 
mouse pancreatic cancer. When p53R172H mutation is crossed into the KC model, the LSL-
KrasG12D/+; p53R172H/+; Pdx-Cre mice (also known as KPC mice) develop PanIN lesions on 
an accelerated schedule and will die of PDAC with a median survival of only 5.5 months 
(67). The KPC mice makes it possible to observe the entire process of mouse pancreatic 
cancer development in a relative short time period. 
To study the expression alternation of PRMT1 during pancreatic cancer development, 
pancreatic tissue sections from both KC and KPC mice at various ages were IHC stained 
with a specific anti-PRMT1 antibody. I observed a positive staining of PRMT1 in both 
PanIN lesions and invasive PDAC lesions but no or very weak staining in mouse normal 
pancreas acinal cells (Fig.6). Moreover, the expression levels of PRMT1 were gradually 
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increased as disease developed from low grade PanIN to high grade PanIN and finally 
PDAC (Fig.7). 
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2.3.3 PRMT1 promotes cancer cell proliferation, migration and invasion in vitro. 
Above evidence clearly demonstrate that expression of PRMT1 increases with severity of 
dysplasia. During the progression of PanIN lesions, the proliferation, mobility and invasive 
ability of pre-cancerous cells gradually increase. The PanIN 3 lesion is used to be called 
Carcinoma in situ or intraductal carcinoma, which reflect the cancerous identity of these 
cells, but the basement membrane surrounding the lesions has not been broken through 
at this stage. When the integrity of basement membrane is destroyed, and cancer cells 
protrude to the surrounding tissues, it can be defined as invasive tumor, and tumor 
metastasis begins from this time point. Based on the observation that PRMT1 is gradually 
overexpressed during PanIN progression, I speculate that PRMT1 may have a promoting 
role in tumor proliferation, migration and invasion. 
To test this hypothesis, MDA28 cells, a cell line with relatively high PRMT1 expression, 
were transfected with siRNA targeting PRMT1 (siPRMT1) or control siRNA (siCtrl), and 
PANC-1 cells, a cell line with relatively low PRMT1 expression, were transfected with 
PRMT1 expression vector (pHA-PRMT1) or control vector (pcDNA3), respectively (Fig.8A 
and C). Cell proliferation was measured by CCK-8 method for four consecutive days after 
transfection (Fig.8B and D). Results showed that overexpression of PRMT1 could 
increase cancer cell proliferation in vitro, while knockdown of PRMT1 did the opposite. 
Meanwhile, the transfected cells were wounded by scratching and maintained for 12 
hours. Cell migration ability was assessed by measuring the cell-free areas in at least 
three fields under microscopy. The results showed that knockdown of PRMT1 attenuated 
the flattening and migration of MDA28 cells (Fig.9A), whereas ectopic expression of 
PRMT1 strongly promoted the flattening and migration of PANC-1 cells (Fig. 10A). Similar 
results were observed in Boyden chamber invasion assay. The invasive ability of 
siPRMT1-transfected MDA28 cells were significantly attenuated (Fig.9B), whereas the 
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level of invasion in PRMT1-transfected PANC-1 cells were much higher than those of 
control cells (Fig. 10B). 
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2.3.4 Inhibiting PRMT1 expression or enzymatic activity decreases PDAC tumor 
growth in vivo.    
The in vitro data that knockdown of PRMT1 can inhibit tumor cell proliferation, migration 
and invasion prompt me to further study the outcome of targeting PRMT1 in vivo. MDA28 
cells were transfected with either siCtrl or siPRMT1, and then injected subcutaneously into 
the flanks of nude mice. The tumor growth was monitored for 17 consecutive days. The 
results showed that knockdown of PRMT1 dramatically inhibited the growth of MDA28 
cells in vivo (Fig.11). 
Since dysregulation of PRMTs, including PRMT1, has been linked to many human 
diseases, such as cancer, the development of PRMT chemical modulators is a steady 
progress in the past several years. Although some pan-PRMT inhibitors showed 
cytotoxicity to various cell types, due to the high homology among PRMT family members, 
how to achieve high potency and selectivity to a specific PRMT protein is still a great 
challenge in drug development. Two small molecule compound, furamidine, also known 
as DB75, and TC-E5003 were recently identified to be PRMT1 specific inhibitors that have 
very low inhibition on other major PRMT members, like PRMT5 and CARM1/PRMT4 (68, 
69). The anti-cancer activity of these two drugs were tested in PDAC models both in vitro 
and in vivo. After DB75 treatment for 48 hours, cultured cancer cells showed typical 
apoptosis phenotype (Fig. 12A). In addition, the cytotoxicity assay showed that both DB75 
and TC-E5003 were toxic to several PDAC cell lines, with IC50 value at micromole level 
(Fig.12B and C). Particularly, BxPC-3 cells, which have wild type KRAS protein, showed 
a relative insensitivity to these drugs. Whether this gene mutation is responsible for the 
insensitivity will be a subject for further investigation. 
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Since DB75 was previously used as an anti-parasite drugs in human, its biological safety 
should be acceptable. Therefore its anti-cancer effect was tested in a mouse model. 
Mouse metastatic pancreatic cancer H7 cells were injected subcutaneously into C57BL/6 
mouse, and low-dose (5mg/kg) and high-dose (20mg/kg) DB75 were intraperitoneally 
administrated to the mice twice every week for three week. During this period, tumor sizes 
were monitored and tumor weights were measured at the end time point. Results showed 
that DB75 did not affect the expression level of PRMT1 (Fig. 13A), which is complied with 
previous report that this drug mainly targets PRMT1 enzymatic activity, not its expression 
(69). However, administration of DB75 dose-dependently inhibited H7 tumor growth in 
vivo, and showed no obvious side effects during this time window (Fig.13B-D).  
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2.4 DISCUSSION 
PRMT1 is the primary type I arginine methyltransferases in mammals, and it has a broad 
spectrum of protein substrates that can be methylated at certain arginine residues. 
Overexpression of PRMT1, or certain splicing variants of it, has been reported in many 
cancer types, such as breast, prostate, lung, colon, bladder cancer and leukemia (30). 
However, the expression and function of PRMT1 in pancreatic cancer have not been 
demonstrated.  
In this chapter, human tissue samples from several types of gastrointestinal (GI) cancers, 
primarily pancreatic cancer, and multiple human PDAC cell lines were utilized to show the 
overexpression of PRMT1 in PDAC. Moreover, statistical analysis shows that high 
expression of PRMT1 is correlated with shorter overall survival time and poorer 
differentiation grade of PDAC patients. The IHC staining results from mouse pancreatic 
cancer models clearly demonstrate the gradually elevated levels of PRMT1 during PanIN 
progression. All these evidence indicate a pro-tumorigenic role of PRMT1 in PDAC 
development. Next, gain- and loss-of-function assays were performed to demonstrate the 
role of PRMT1 in promoting cancer cell growth, migration and invasion in vitro. Last, two 
recently identified small molecular PRMT1 specific inhibitors were tested on PDAC cells 
both in vitro and in vivo, and they showed cytotoxicity at micromolar level to PDAC cells. 
The PRMT1 expression status and functions in GI cancers are less studied based on 
previous publications, and some controversy exists among these studies (70-73). For 
example, PRMT1 gene expression was found to be upregulated in colon cancer tissues, 
and this upregulation was associated with poor prognosis (72, 73). Similarly, in human 
hepatocellular carcinoma (HCC) cells, overexpression of PRMT1 promoted cancer cell 
migration and invasion (71). However, another study in gastric cancer revealed a nuclear 
expression of PRMT1 in cancer cells, and those authors claimed that lower expression of 
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PRMT1 was associated with recurrence after adjuvant chemotherapy and poor prognosis 
(70). In my study, the IHC staining results clearly showed the overexpression of PRMT1 
in pancreatic cancer tissues than normal acinar or ductal cells. The functional assay also 
demonstrated a tumor-promoting function of PRMT1 under my experimental conditions. 
From the data in my present study and previous reports, it seems that PRMT1 may have 
a dual function as a tumor promoter or suppressor. These phenomena may reflect a 
context- or cell type-dependent function of PRMT1, or distinct splicing variants of PRMT1 
may be dysregulated in different cancer types so that the overall PRMT1 expression could 
not be used as a prognostic marker alone. All these possibilities warrant further study. 
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CHAPTER 3. HSP70 IS A NOVEL SUBSTRATE OF PRMT1 
3.1 INTRODUCTION 
The results in Chapter 2 outlined a tumor-promoting function of PRMT1 in pancreatic 
cancer. However, how this function is achieved at the molecular level is not known. Since 
PRMT1 is an enzyme, which is responsible for methylating certain arginine residues in its 
substrate proteins, it is logical to postulate that PRMT1’s function in cancer development 
is mainly mediated by its enzymatic activity. The best known substrate for PRMT1 is 
histone H4. PRMT1 can specifically deposits a MMA or ADMA mark on histone H4 at 
arginine 3 (H4R3), which is a transcription activation marker (74). Although the underlying 
mechanisms that how H4R3 methylation activates corresponding gene transcription have 
not been completely elucidated, the protein complex containing methylarginine effector 
molecule TDRD3 and topoisomerase IIIB (TOP3B) is proved to play a role in this process 
(75, 76). 
Large numbers of non-histone substrates of PRMT1 have also been identified. By 
methylating diverse proteins localized at different subcellular compartments, PRMT1 is 
involved in many biological processes, such as DNA damage repair, RNA processing, 
receptor signal transduction etc., which may contribute to tumor cell survival, migration 
and invasion (30). Compared with histone arginine methylation, which may affect gene 
expression at the transcription level, arginine methylation of non-histone proteins at the 
post-transcription level is a quick, energy-efficient and perhaps a reversible way to 
precisely regulate the function of a specific protein to help cells adapt to the ever-changing 
microenvironment. Thus to identify and study novel substrate proteins of PRMT1 that may 
function in cancer biology is the primary focus of this chapter. 
As it is mentioned in Chapter 1, HSP70 family has several members that serve critical 
survival functions in cells, particularly cancer cells. Moreover, some studies also revealed 
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that lysine or arginine methylation of HSP70 may affect its function as a molecular 
chaperon or transcription co-activator (61, 62, 77, 78). It is plausible that these 
modifications expand or regulate the chaperon client scope of HSP70 proteins and 
therefore affect their biological functions. In my study, I found that at least four members 
of HSP70 family are binding partners of PRMT1. This observation can be interpreted as 
either HSP70 proteins may facilitate PRMT1 folding, or HSP70 proteins may be a new 
group of substrates of PRMT1.   
In this chapter, first the protein-protein interaction of four representative HSP70 family 
members with PRMT1 is studied by Co-immunoprecipitation (Co-IP) assay in mammalian 
cells and GST pull-down assay in vitro. Next, the essential domain for interaction is 
determined by using a series of truncated HSP70 protein variants, and the structure of 
PRMT1-HSP70 complex is studied by molecular modeling. Last, the potential methylation 
sites are determined by mass spectrometry and in vitro methylation assay with 
corresponding peptides and recombinant proteins. 
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3.2 MATERIAL AND METHODS 
Plasmids and Cloning Procedures 
Full-length HSPA1A (HSP70), HSPA5 (GRP-78), HSPA8 (HSC70) and HSPA9 (GRP-75) 
plasmids were purchased from OriGene Technologies, and they are in the pCMV6-Entry 
vector backbone with C-terminal Myc-DDK tag. GFP-PRMT1 and GST-PRMT1 plasmids 
were gifts from Dr. Mark T. Bedford at UT MD Anderson Cancer Center. The HSP70 and 
PRMT1 gene truncations were PCR-amplified by using Herculase II Fusion Enzyme 
(Agilent Technologies) and inserted back to the original vectors or GEX-KG vector for 
bacterial expression. Arginine-to-alanine mutant HSP70 vectors were generated by 
overlap extension PCR method. All other plasmids used in this chapter have been 
described in Chapter 2. 
siRNAs, Antibodies, Peptides and Compounds 
Anti-Myc and anti-HA mouse monoclonal antibodies were purchased from OriGene 
Technologies. Anti-HSP70 antibody was from Enzo Life Sciences. Anti-HSC70, anti-
GRP78, anti-GRP75 and anti-GST antibodies were from Santa Cruz Biotechnology. Anti-
asymmetric dimethyl arginine antibody, ASYM24, was from EMD Millipore Corporation. 
All other antibodies and siRNAs have been described in Chapter 2. HSP70 wild type and 
mutant peptides were custom synthesized by ApexBio Technology as 
R3 GGRGGFGGRGGFGGRGGFG 
3RA GGAGGFGGAGGFGGAGGFG 
R416 GVMTALIKRNSTIPTKQTQ 
R416A GVMTALIKANSTIPTKQTQ 
R447 VLIQVYEGERAMTKDNNLLG 
R447A VLIQVYEGEAAMTKDNNLLG 
R458 MTKDNNLLGRFELSGIPPAP 
R458A MTKDNNLLGAFELSGIPPAP 
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 Immuoprecipitation and Immunoblotting assay  
For immunoprecipitation assay, cells were lyzed in Pierce IP Lysis Buffer (Thermo Fisher 
Scientific) supplemented with protease inhibitor cocktail, sodium fluoride, sodium 
orthovandate, and phenylmethylsulfonyl fluoride (PMSF). Cell lysates were incubated with 
coresponding antibody or antibody conjugated magnetic beads overnight at 4°C on a 
rotator. If antibody were used for IP, Protein A/G plus agarose (Santa Cruz) was then 
added and the reactions were further incubated at 4°C for 2 h. After washing with PBST 
for four times, 5min each, protein complexes were released from agarose by boiling for 
10min in 2× SDS-PAGE loading buffer or by elution with tag peptides. Immunoblotting was 
performed to detect specific protein in the complex as it is described in Chapter 2. 
Protein Purification from Bacterial Cells or HEK293T Cells 
GST-tagged proteins were expressed in BL21 (DE3) bacterial cells (NEB) and induced by 
100μM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Fisher Scientific). Then 
bacterial cells were lyzed by Pierce pull-down lysis buffer supplemented with protease 
inhibitor cocktail, and purified by using Pierce Glutathione Magnetic Agarose Beads 
(Thermo Fisher Scientific). Protein complexes were eluted by 50 mM reduced glutathione. 
Myc- or HA-tagged proteins were expressed in HEK293T cells by transient transfection 
and cells were lysed in lysis buffer and purified by Myc or HA peptide conjugated magnetic 
beads and washed extensively with PBST. Purified proteins were eluted by Myc or HA 
peptide (ApexBio Technology). 
Immunofluorescence assay  
Cells grown in Falco 4-well chambered cell culture slides were fixed with 4% 
paraformaldehyde in PBS for 10min and rendered permeable by further treatment with 
0.2% Triton X-100 for 10min. Then fixed cells were blocked by incubation with 5% BSA 
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solution for 30 min. The PRMT1 antibody and HSP70 antibody (Enzo Life Sciences, ADI-
SPA-810-F) were 1:200 diluted and mixed in 5% BSA solution and incubated with cells 
overnight at 4°C. After washing with PBST for three times, cells were incubated with Alexa 
594-labelled anti-rabbit IgG and Alexa 488-labelled anti-mouse IgG antibodies (Thermo 
Fisher Scientific) for 2h at room temperature with gentle shaking. Cells were then washed, 
mounted with prolong gold antifade reagent with DAPI (Thermo Fisher Scientific), viewed, 
and photographed under a fluorescence microscope (Leica). 
In vitro methylation assay 
Synthesized peptides or purified recombinant proteins were incubated with 2μg PRMT1 
recombinant protein (Origene Technologies) and 2μCi S-[methyl-3H]-adenosyl-methionine 
(Perkin Elmer) in 20μl methylation buffer (50mM Tris·HCl, pH 8.0, 150mM NaCl, 1mM 
EDTA). Reactions were incubated at 30°C for 3h. Results were measured by either liquid 
scintillation counting (LSC) or autoradiography.  For LSC, 10μL mixture was dotted onto 
a small circular nitrocellulose membrane and washed three times with methylation buffer. 
Then the membrane was air dried and immersed in ScintiVerse II Cocktail (Thermo Fisher 
Scientific) in a glass scintillation vial and measured by Liquid Scintillation Counter 
(Beckman Coulter). The DPM for each peptide is calculated as net DPM = DPM (wild type) 
– DPM (mutant). For autoradiography, the reaction mixture was boiled in loading buffer 
for 5min and then separated by SDS-PAGE and transferred to polyvinylidene difluoride 
membrane. Membrane was treated with EN3HANCE Spray (Perkin Elmer) and exposed 
to film at -80°C for 7-10 days. 
Protein sequence alignment 
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All the protein sequences were retrieved from UniProt Protein Database in FASTA format. 
Multiple sequence alignment was performed use online web tool Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Mass Spectrometry Analysis 
HEK293T cells were co-transfected with HA-PRMT1 and Myc-HSP70 plasmids and 
cultured for 48h. Then cells were lysed in Pierce IP Lysis Buffer supplemented with 
protease inhibitor cocktail. Cell lysate was incubated with anti-Myc antibody conjugated 
magnetic beads overnight at 4 °C, followed by washing five times with lysis buffer. 
Immunoprecipitates were boiled in SDS sample buffer for 5min and resolved by 10% SDS-
PAGE gel, followed by Coomassie blue staining. Band corresponding to HSP70 was 
excised and subjected to in-gel digestion with trypsin. Then samples were sent to the 
University of Texas MD Anderson Cancer Center Proteomics and Metabolomics Facility 
for MALDI-TOF analysis using an Ultimate capillary LC system (LC Packings) coupled to 
a QSTARXL quadrupole time-of-flight mass spectrometer (Applied Biosystem/MDS 
Sciex). 
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3.3 RESULTS 
3.3.1 PRMT1 interacts with four members of HSP70 protein family.  
Histones are classic methylation substrates of PRMT1. To identify novel non-histone 
substrates of PRMT1, first I screened for PRMT1-interacting proteins using affinity 
purification combined with mass spectrometry. I found that PRMT1 bound to endogenous 
HSP70 and HSC70 in HEK293T cells (Fig.14). My observation is consistent with previous 
studies that HSP70 protein was identified to interact with PRMT1 in other systems (79-
81). Moreover, some studies also identified other HSP70 family member, such as GRP75 
and GRP78, in protein complexes with PRMT1 (79-81). To further validate these 
observations, I tested the protein-protein interactions (PPIs) between four major HSP70 
family members (HSP70, HSC70, GRP75 and GRP78) and PRMT1 using co-
immunoprecipitation (Co-IP) assay.  
First, Myc-tagged HSP70, HSC70, GRP75 and GRP78 were co-transfected to human 
293T cells with HA-tagged PRMT1, respectively. Co-IP results showed that these four 
Myc-tagged exogenous proteins could bind to exogenous HA-PRMT1 (Fig.15A). Next, 
HA-tagged PRMT1 was transfected to 293T cells, and binding of HA-PRMT1 with four 
endogenous HSP70 family members was demonstrated (Fig.15B). Finally, the 
endogenous interaction of HSP70 and PRMT1 under normal culture conditions was 
confirmed in pancreatic cancer cell line L 3.7 (Fig. 15C). These evidence demonstrate that 
at least four members in HSP70 protein family can interact with PRMT1 in human cells. 
Since HSP70 is the representative and best studied protein in this family, and its 
dysregulation is observed in pancreatic cancer, my following study will mainly focus on 
HSP70 and the possible PTMs on it. 
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In addition to Co-IP assay, the subcellular localization of PRMT1 and HSP70 was also 
studied in both normal cells and pancreatic cancer cells. It showed that in mouse 
embryonic fibroblast (MEF) cells, HSP70 expression was very low under normal culture 
condition, and was dramatically induced after heat shock treatment (Fig.16). The HSP70 
protein was distributed in both cytoplasm and cell nucleus, but was more nuclear 
accumulated after heat shock treatment, which is consistent with previous reports (82, 83). 
In contrast, HSP70 protein was mainly localized in cell nucleus in PANC-1 and MIA PaCa-
2 pancreatic cancer cells, and its expression was constantly high even without heat shock 
treatment (Fig.17). In all mouse and human cells, PRMT1 was mainly expressed in cell 
nucleus, while it was also observed in the cytoplasm and/or cell membrane at a lower level 
(Fig. 16 and 17). Moreover, the expression level of PRMT1 was not affected by heat shock 
treatment when compared with HSP70. The Immunofluorescence results not only indicate 
the possible interaction between HSP70 and PRMT1 due to their co-localization, but also 
imply important role of HSP70 in cell nucleus of cancer cells. 
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3.3.2 Binding domain of HSP70 with PRMT1 is determined. 
HSP70 mainly functions as a molecular chaperon to facilitate folding and re-folding of 
other proteins. There is a nucleotide binding domain (NBD) at the amino terminus of 
HSP70 that has an ATPase function, and a substrate binding domain (SBD) at the 
carboxyl terminus that is responsible for binding of client protein or peptides, and a linker 
region between these two domains (Fig. 18A)(84). The chaperon function of HSP70 is an 
energy-consuming process that depends on the hydrolysis of ATP. Thus modifications 
added to either the NBD or SBD of HSP70 may affect its affinity to ATP/ADP or substrate 
protein, respectively, and therefore influence its biological functions.  
To identify the region of HSP70 that is required for its interaction with PRMT1, I generated 
a series of Myc-tagged deletion mutants of HSP70 and co-transfected them with HA-
tagged PRMT1 to 293T cells (Fig. 18B). Immune complexes of HA-tagged PRMT1 were 
tested for the presence of Myc-tagged HSP70 fragments. As shown in Fig. 19A, the 
interaction assays suggested that amino acids M410-E460 of HSP70 are essential to 
mediate HSP70 interaction with PRMT1. Interestingly, I also found that deletion either the 
N-terminal part or C-terminal part regarding motif M410-E460 dramatically increased its 
binding affinity to PRMT1 when compared with full-length HSP70 (compare lane 2, 4 with 
lane 7 in Fig. 19A). The reason may be that removal of the obstructive motif at either side 
can expose the binding domain more efficiently. Thus it is more accessible for PRMT1 to 
interact with the binding pocket. It is particularly reasonable when we consider the fact 
that the carboxyl terminus (~500-641 amino acids) composes a helical lid structure that 
may mask the binding domain and impede the possible protein-protein interaction.  
To further pinpoint the binding motif for this interaction, amino acids 410 to 460 of HSP70 
were divided into three fragments and similar interaction assays were performed. To my 
surprise, it seemed that all the fifty amino acids were contributive to the observed 
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interaction, because binding affinity gradually increased when the carboxyl terminus 
extended from 430 to 441 and 460 (Fig. 19B). I speculate that there may be a small core 
binding motif in domain 410-460, and the other proximal amino acids around it are also 
supportive to this interaction.   
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To further confirm the mapping results I got in 293T cells and determine whether the 
binding of HSP70 with PRMT1 is a direct interaction, in vitro GST pull-down assay was 
performed. A series of HSP70 deletion mutants were expressed in bacteria as GST fusion 
proteins. Equal amount of fusion proteins of each deletion mutant were immobilized to 
glutathione beads, and then incubated with cell lysate from 293T cells transfected with 
HA-tagged PRMT1 (Fig. 20). Immunoblotting results showed that the GST tag had a 
medium level interaction with HA-PRMT1 protein (Fig. 20 Lane1). This is not desired in 
the assay, but is consistent with a previous study showing that PRMT1 could interact with 
Glutathione S-transferase P (81). If we exclude the GST tag effect, the pull-down data 
recapitulated the mapping results in 293T cells, in which the 1-441 and 1-460 fragments 
had the best binding affinity with PRMT1, while 1-388 fragment had the lowest, maybe a 
background level, binding affinity. The only difference came from the 410-641 fragment. 
In mammalian cells, it had a very high affinity with PRMT1, but as a GST fusion protein, 
the binding affinity dramatically decreased (compare Fig. 20 Lane 2 with Fig. 19A Lane 
2). The reason for this difference may be that fusion N-terminus of 410-641 fragment to 
GST tag, a large peptide roughly 26 kDa, can alter the local polypeptide conformation near 
410-460 binding motif, and therefore influences its binding affinity with PRMT1. While in 
mammalian expression system, the HA tag is very small (less than 4 kDa) and is attached 
to the C-terminus of 410-641 fragment, which probably has little effect on its binding 
activity. 
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With similar method, several deletion mutants of human PRMT1 were generated to identify 
the interaction motif of PRMT1 required for its binding to HSP70 (Fig. 21). The strategy to 
construct these deletion mutants vectors are based on the functional domain distribution 
of PRMT1. However, it was so surprising to find that some truncated PRMT1 proteins 
could not be stably expressed in 293T calls under my experimental condition (Fig. 22). 
Compared with full-length PRMT1 variant 1, deletion either the N-terminus or C-terminus 
of PRMT1 significantly decreased their protein stability (compare Lane 2, 3, 4 and 5 vs. 
Lane 6 in Fig. 22). In the same experiment, co-transfected Myc-tagged HSP70 could be 
used as the internal control to demonstrate that the expression efficiency of these vectors 
are at same level (Fig. 22 lower panel). Therefore, without the prerequisite to get equal 
amount of truncated proteins, the immunoprecipitation mapping assay could not be 
conducted. 
The stability issue of PRMT1 protein has not been clearly studied before, but the structure 
analysis may provide some explanations. All PRMTs have a conserved core structure 
consisting of an AdoMet binding domain and a barrel-like domain (green and yellow 
domains in Fig. 21), which is about 310 amino acid long (85, 86). In PRMT1, there is a 
small dimerization arm domain (blue in Fig. 21) between the other two function domains, 
and homodimerization or homo-oligomerization of the PRMT1 subunit is important for its 
enzymatic activity (85). Besides the conserved 310 amino acids, PRMT1 can be produced 
up to seven protein isoforms, all varying in their N-terminal domain (87). The PRMT1 
variant 1 used in my experiment is a relative long isoform that the N-terminal variable 
sequence is about 60-70 amino acids long. This may explain the observation that fragment 
66-371 had a comparable expression level with full length protein (Lane 1 vs. Lane 6 in 
Fig. 22), because it contains nearly all the 310 amino acids long conserved structure. 
However, because all the conserved regions, an AdoMet binding domain, a dimerization 
66 
 
domain, and a barrel-like domain, fold together to form a single functional unit, deletions 
of virtually any portion of the conserved core structure will result in loss of structural 
integrity. Therefore, the truncated proteins will be quickly eliminated by cell intrinsic protein 
degradation system since they are regarded as improperly produced proteins by cells. 
This may explain why all other PRMT1 deletion mutants are less stable in 293T cells 
(compare Lane 2, 3, 4 and 5 vs. Lane 6 in Fig.22).   
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3.3.3 Two conserved arginine residues of HSP70 are methylated by PRMT1. 
Based on above protein-protein interaction analysis, I postulate that HSP70, as well as 
some other members in this protein family, may be a novel substrate of PRMT1.  Glycine- 
and arginine-rich (GAR) sequence is the preferential methylation motif recognized by 
PRMT1, but protein sequence analysis failed to show any typical GAR motif in HSP70 
protein. Therefore I planned to use mass spectrometry to de novo identify any possible 
arginine methylation in HSP70 protein. First, I used a specific antibody against asymmetric 
dimethylated arginine (ASYM24) to demonstrate the function of ectopically expressed 
PRMT1. Results showed that overexpression of PRMT1 could increase the overall 
methylation level of endogenous proteins, while knockdown of PRMT1 did the opposite 
(Fig. 23A). Particularly, the whole-membrane blotting also revealed that there were many 
proteins between 56 to 100 KDa that had arginine methylation modifications (Fig. 23A left 
panel), which may include HSP70.  
To do the mass spectrometry analysis, Myc-tagged HSP70 and HA-tagged PRMT1 were 
co-transfected into 293T cells, and HSP70 protein was purified by immunoprecipitation 
with anti-Myc antibody conjugated to magnetic beads. Empty vector served as control. 
The prominent band corresponding to Myc-HSP70 was excised and subjected to mass 
spectrometry (Fig. 23B). Due to the trypsin digestion protocol we used and the amino acids 
composition of HSP70 protein, the mass spectrometry assay only covered about 70% 
peptide sequence of the whole HSP70 protein. The result indeed showed some 
methylated lysine and arginine residues, some of which were consistent with previous 
reports, meaning our assay was successful. The data analysis identified arginine 416 
(R416) as a methylation site (Fig. 23C). This site is of great interest because it is located 
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in the 410-460 protein binding region, and a similar study of PRMT5 showed that the 
substrate binding region and methylation sites are very close to each other (88).  
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Protein sequence analysis showed that between amino acid 400-500, there are only four 
arginine residues (R416, R447, R458 and R469) in HSP70 protein, and arginine 469 has 
been proved to be methylated by CARM1/PRMT4 rather than PRMT1 in a recent study 
(62). Multiple sequences alignment revealed that among the remaining three arginine 
residues, two of them, R416 and R447, are much conserved and R458 is less conserved 
(Fig. 24). Particularly, R416 and R447 are not only highly conserved among different 
members of HSP70 family (Fig. 24A), but also conserved among various species during 
evolution history (Fig. 24B), suggesting that methylation on these residues may be 
functionally important. To verify whether these three arginine residues can be methylated 
by PRMT1, 20-amino-acids long peptides containing the three arginine residues (R416, 
R447 and R458), and the corresponding methylation site arginine-to-alanine (R-to-A) 
mutant peptides (R416A, R447A and R458A) were synthesized for the in vitro methylation 
assay. The mutant peptides were used as negative controls and a well-established 19-
amino-acid peptide containing three GAR repeats (R3 in Fig. 24C) was used as a positive 
control (85). Results showed that when R416 and R447 peptides were incubated with 
purified PRMT1 and 3H labeled S-Adenosyl methionine, the methyl group donor, there 
was a dramatic tritium incorporation detected by liquid scintillation counting (LSC). In 
contrast, R458 peptide failed to show such incorporation when compared with R458A 
mutant peptide (Fig. 24C).  
To further confirm that arginine 416 and 447 can be methylated in the natural conformation 
of HSP70, three single R-to-A mutant (R416A, R447A and R458A) and a triple R-to-A 
mutant (triple RA) HSP70 expression vectors were constructed. GST-tagged wildtype and 
mutant HSP70 proteins were purified from bacteria and then used for in vitro methylation 
assay. Methylation of HSP70 was measured by autoradiography. As it is shown in Fig. 
24D, wildtype HSP70 protein was methylated by PRMT1, and mutation either R416 or 
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R447 to alanine decreased about half of the methylation level, while mutation R458 to 
alanine did not affect the methylation level. If all three arginine residues were mutated to 
alanine, there was no methylation that could be detected by autoradiography. This 
observation suggests that R416 and R447 are the primary PRMT1 methylation sites of 
HSP70. 
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3.4 DISCUSSION 
Emerging evidence suggest that PRMTs use both histone and non-histone proteins as 
substrates to modulate important biological processes during embryo development, cell 
growth and pathogenesis (17, 30, 89, 90). Methylation on both lysine and arginine 
residues of HSP70 protein has been known for decades, but the exact methylation sites, 
the methyltransferases involved in these reactions and the biological functions of such 
modifications are not clearly understood (91). Particularly, during the period of my 
dissertation study, the first evidence of arginine methylation (R469) of HSP70 mediated 
by PRMT4/CARM1 and its role in regulating gene activation was reported (62). However, 
in my present study, I provide evidence that two other highly conserved arginine residues 
of HSP70 are methylated by PRMT1, the founding member of type I PRMTs. Since both 
HSP70 and PRMT1 are evolutionally conserved proteins and can be found in nearly all 
eukaryotes, from yeast to human being, the PRMT1-mediated methylation of HSP70 may 
have a crucial role in life maintenance.  
First, I used Co-IP assay to demonstrate that at least four members of HSP70 family, 
HSP70, HSC70, GRP75 and GRP78, could interact with PRMT1 both in vitro and in vivo. 
Although all of the proteins have similar structures, their functions are different due to their 
various subcellular localizations (57). Their interactions with PRMT1 not only suggest a 
broader substrate scope of PRMT1 but also indicate a conserved protein arginine 
methylation mechanism across HSP70 family members during evolution. But whether the 
modifications affect their functions in a similar way or different ways is an intriguing 
question that warrants further investigation.   
Next, the interaction domain of HSP70 with PRMT1 was determined by using a series of 
HSP70 deletion mutant proteins. Result showed that amino acids 410 to 460 were 
essential for this protein-protein interaction. The following mass spectrometry and in vitro 
75 
 
methylation assay revealed two methylation sites located in the binding motif. Since this 
motif is the core part of substrate binding domain of HSP70, and several conserved 
arginine residues are predicted to facilitate either the intra-domain interactions of HSP70 
protein or the binding of substrate peptides with HSP70 substrate binding pockets (92), 
methylation of these arginine residues may disrupt the hydrogen bonds required for such 
molecular interaction and thus change the binding activity of HSP70 to certain substrate 
peptides/proteins. For example, a recent study revealed that the amino acids 445 to 450 
motif was responsible for the binding of HSP70 with superoxide dismutase 2 (SOD2) in 
the cytosol to transfer this enzyme to the mitochondria for activation (93). Whether this 
interaction is regulated by methylation of Arginine 447 remains further investigation.      
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CHAPTER 4 ARGININE METHYLATION OF HSP70 REGULATES 
PANCREATIC CANCER DRUG RESISTANCE  
4.1 INTRODUCTION 
In Chapter 3, I demonstrated that HSP70 was a novel substrate of PRMT1 and two 
conserved arginine residues (R416 and R447) of HSP70 could be methylated by PRMT1 
in vitro and in vivo. In this chapter, the biological consequences of these specific post-
translational modifications will be studied. The question to be addressed is how HSP70 
methylation will affect the biology of pancreatic cancer. Chemotherapeutic drug resistance 
is a commonly observed problem in pancreatic cancer treatment. Since HSPs are critical 
proteins involved in cell stress responses, and induced drug resistance is a typical cancer 
cell response under severe and continual stress, my study will focus on how arginine 
methylation of HSP70 regulates drug resistance in pancreatic cancer. 
Gemcitabine is currently the first-line chemotherapeutic agent to treat pancreatic cancer. 
However, it only provides little benefit to prolong the survival and to moderately improve 
the quality of life of pancreatic cancer patients (94). Even combined with other chemo 
drugs, such as erlotinib or nab-paclitaxel, improvement in the survival of patients with 
advanced pancreatic cancer was still minimal, albeit statistically significant (16, 95). 
Gemcitabine is known to induce apoptosis of malignant cells after it is transported into 
cancer cells and phosphorylated by deoxycytidine kinase to become its active metabolite. 
But a high degree of inherent and acquired resistance to gemcitabine is often observed in 
clinical practice, which limits the efficiency of this chemotherapy (96). Overexpression of 
HSP70 in pancreatic cancers, as well as in some other cancer types, has been shown to 
confer drug resistance to gemcitabine (51, 97, 98), but the detailed mechanisms are not 
well understood. 
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Though PRMT1 plays important roles in various biological processes, its function in drug 
resistance is rarely studied. A research group demonstrated that PRMT1-mediated 
methylation of EGFR regulates acquired resistance to cetuximab, an EGRF targeting 
monoclonal antibody (99). Another group reported that PRMT1 may be a co-activator of 
pregnane x receptor in activating multidrug resistance protein 1 (MDR1) gene during 
acquired drug resistance in breast cancer cells (100). However, the role of PRMT1, 
particularly as a methyltransferase, in pancreatic cancer drug resistance has never been 
studied. Based on the evidence from last chapter, I postulate that PRMT1-mediated 
methylation of HSP70 protein is involved in the regulation of pancreatic cancer drug 
resistance. 
In this chapter, first the HSP70 knock-out pancreatic cancer cells were generated. Then 
wildtype and methylation sites mutant HSP70 proteins were reconstituted into these cells 
to compare their different responses to gemcitabine treatment. In addition, their responses 
to other types of stress, like glucose deprivation, oxidative stress, etc., were also studied.  
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4.2 MATERIAL AND METHODS 
HSP70 and PRMT1 knock-out cell lines. 
A CRISP-Cas 9 system was used to generate gene specific knock-out cell lines according 
to reference (101). Briefly, the first 100bp of coding sequences of human HSPA1A/B and 
PRMT1 gene were analyzed for guide sequences design by an online CRISPR Design 
Tool (http://crispr.mit.edu/). The guide sequence for HSPA1A/B is forward: 5’-
ATGGCCAAAGCCGCGGCGAT-3’ and reverse: 5’-ATCGCCGCGGCTTTGGCCAT-3’. 
The guide sequence for PRMT1 is forward: 5’-CATGATGCAGTTCGCGGCCT-3’ and 
reverse: 5’-AGGCCGCGAACTGCATCATG-3’. The forward and reverse oligoes were 
annealed with each other and inserted into vector pSpCas9(BB)-2A-Puro (Addgene 
#62988), which was pre-digested by BbsI  restriction endonuclease. The recombinant 
plasmid was transfected into MIA PaCa-2 cells and cells were treated with puromycin 
(1µg/ml) for 48-72 hours. After puromycin selection, single cell clones were seeded into 
96-well plates by flow cytometry. After 10-14 day culture, each survival cell clone was 
tested for targeting gene knock-out by both Western blot and genomic DNA sequencing. 
In vitro cytotoxicity assay  
A Cell Counting Kit-8 (CCK-8) method was used to measure the cytotoxicity of 
gemcitabine to different MIA PaCa-2 cell groups. Cells were seeded in 96-well plates 
(Corning Incorporated, Corning, NY, USA) at a density of 5,000 cells per well and 
incubated for 24 h in DMEM complete medium (Gibco, New York, NY, USA), then in 
medium containing 1-200 μM of gemcitabine for another 48 h. Vehicle treated control cells 
were included. Subsequently, culture medium was removed and fresh medium containing 
10% CCK-8 reagent (Dojindo Molecular Technologies, Rockville, MD, USA) was added to 
each well, and the plates were incubated at 37°C for 1h. Then, the absorbance at 450 nm 
of each well was measured using a spectraMAX-M5 microplate reader (Molecular 
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Devices, Sunnyvale, CA, USA). All tests and analyses were performed in triplicate. Drug 
cytotoxicity was calculated as the fraction of reduced OD450 value after drug treatment to 
the OD 450 value of untreated cells. A graph of cytotoxicity versus concentrations of 
gemcitabine was plotted. 
Glucose deprivation and gemcitabine treatment to cancer cells 
24h after transfection, control cell group was treated with gemcitabine diluted in high 
glucose DMEM medium (with 4500mg/L glucose, Sigma-Aldrich, St. Louis, MO, USA), 
while glucose deprivation cell group was treated with gemcitabine diluted in DMED 
medium without glucose and sodium pyruvate (Gibco, New York, NY, USA). After 48h 
culture, the cytotoxicity was measured as described above. 
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4.3 RESULTS 
4.3.1 HSP70, but not PRMT1, knock-out cells are generated. 
To study the biological functions of PRMT1-mediated HSP70 arginine methylation, first 
the HSP70 and PRMT1 knock-out cell lines were generated to delete endogenous 
proteins. A CRISPR/Cas 9 system was used to generate such cell lines. After single cell 
clone selection and culture, eight HSP70 knock-out MIA PaCa-2 cell clones were 
successfully generated (Fig. 25). Western blot showed that endogenous HSP70 protein 
was completely deleted (Fig. 25B) and DNA sequencing results demonstrated indel 
mutations in the CRISPR target region (Fig. 25C).  Meanwhile, the HSP70 wildtype (WT) 
control cells were also generated by transfection of a scramble sgRNA followed by the 
same puromycin selection procedure.   
In contrast, the generation of PRMT1 knock-out cell line was not successful. After single 
cell clone selection, Western blot and DNA sequencing results showed that in several cell 
clones, endogenous PRMT1 protein was indeed depleted (Fig. 26A and C), but these cells 
could not properly grow and proliferate. Extreme giant cells, about four to five times larger 
than normal cells, were observed in the first several days (yellow arrow in Fig. 26B IV), 
and then those giant cells became bubble-like structure and underwent apoptosis (red 
arrow in Fig. 26B IV). Finally, all PRMT1-depleted cell clones died in about 10 days.   
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4.3.2 HSP70 arginine methylation is essential for cancer cell drug resistance to 
gemcitabine. 
To study how HSP70 arginine methylation influences cancer cell drug resistance, first, I 
compared the cytotoxicity of gemcitabine to HSP70 wildtype (WT) and eight knock-out 
(KO) cell clones (Fig. 27). Results showed that in general, loss of HSP70 expression 
sensitized MIA PaCa-2 cells to gemcitabine. Five out of eight HSP70 knock-out cell clones 
showed increased cytotoxicity in a wide range of gemcitabine concentration (Fig. 27). This 
observation is consistent with previous studies and demonstrated the role of HSP70 in 
promoting chemotherapeutic drug resistance of cancer cells (51, 97).  
Some members in heat shock protein 70 family, like GRP78 and GRP75, are glucose-
regulated proteins. Their expression is induced by glucose shortage and is linked to 
multiple cellular processes (102). Similarly, HSP70 was also reported to play a role in the 
maintenance of normal cell physiology during glucose deprivation stress (103). Therefore 
I studied whether glucose level contributes to HSP70-mediated gemcitabine resistance. 
Results showed that glucose deprivation sensitized HSP70 knock-out MIA PaCa-2 cells 
to gemcitabine treatment, and this sensitization was more prominent at low drug 
concentration (Fig. 28).   
 
Figure 27. HSP70 depletion sensitizes MIA PaCa-2 cells to gemcitabine treatment. 
HSP70 wildtype (WT) MIA PaCa-2 cells and eight HSP70 knock-out (OK) cell clones were 
treated with gemcitabine at different concentrations for 24h. Relative cytotoxicity was 
measured using a CCK-8 method. 
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To test how arginine methylation influences HSP70-mediated drug resistance, first, the 
effects of wildtype HSP70 protein were validated in MIA PaCa-2 cells. Results showed 
that ectopic expression of wildtype HSP70 protein in HSP70 knock-out cells could restore 
the normal level of drug resistance to gemcitabine (Fig.29). Next, three single methylation 
site arginine-to-alanine mutant, R416A, R447A and R458A, and one triple methylation 
sites arginine-to-alanine mutant, 3Muts, were reconstituted into HSP70 knock-out cells, 
respectively. Relative cytotoxicity of gemcitabine to each cell group was measured and 
compared (Fig.30). Results showed that reconstitution of wildtype HSP70 rescued cell 
drug resistance to a similar level of normal MIA PaCa-2 cells. HSP70 R458A mutant could 
rescue most part of drug resistance when compared with wildtype HSP70. In contrast, 
R416A and R447A mutants could only rescue about half of the drug resistance level, and 
3Muts HSP70 almost lost the ability to rescue drug resistance. Above evidence suggests 
that methylation of R416 and R447, rather than R458, is essential for drug resistance 
function of HSP70 in MIA PaCa-2 cells. 
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4.4 DISCUSSION 
In this chapter, I demonstrated that arginine methylation of R416 and R447 were essential 
for HSP70-mediated drug resistance against gemcitabine by using HSP70 knock-out cells 
and wildtype and a series of methylation site mutant HSP70 proteins.  Several studies 
have shown that overexpressed HSP70 protein increased drug resistance against 
gemcitabine in multiple cancer cells, and the mechanism was associated with cell 
apoptosis and/or autophagy (51, 97, 98). All of these studies mainly focused on the 
expression level of HSP70 protein, and used a bioflavonoid, quercetin, to suppress HSP70 
expression and therefore to sensitize cancer cells to gemcitabine treatment. However, one 
of these studies (97) and my study found that gemcitabine treatment alone did not affect 
HSP70 expression level (data not shown), which means that HSP70-mediated drug 
resistance may not be achieved by increasing HSP70 expression level, but changing its 
chaperone activity. If it is the case, post-translational modifications (PTMs) of HSP70 
would be a possible way to quickly regulate HSP70 chaperone activity under stress 
conditions. 
The binding of HSP70s to their client proteins is determined by the conformation of the C-
terminal lid domain, which in turn is regulated by nucleotide binding and hydrolysis in the 
N-terminal nucleotide binding domain. Therefore, PTMs of HSP70 regulate its chaperone 
activity mainly by two mechanisms, changing its ATPase enzymatic activity and/or 
affecting its binding affinity to client proteins. Some examples include discoveries that 
acetylation at lysine 77 (K77) of HSP70 increased its ATPase enzymatic activity (104), 
and methylation at lysine 561 (K561) of HSC70 reduced its affinity to a client protein, α-
synuclein (α-Syn) (61). In addition, a recent study also showed that methylation at arginine 
469 (R469) of HSP70 was involved in TFIIH recruitment, its association with chromatin, 
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and gene transcription, which was distinct from its “classic” function as molecular 
chaperone (62).  
In my research, the molecular mechanisms how methylation of R416 and R447 influences 
HSP70 function in drug resistance await for further study. By comparing the ADP-bound 
and ATP-bound crystal structures of DnaK, the human HSP70 homologue in E. coli, I 
found that R416 residue is located in the interface between the NBD and SBD of the ATP-
bound HSP70 (data not shown). Because the interaction of NBD with SBD is critical for 
the allosteric activation of HSP70 (105-107), the putative location of R416 may suggest 
its role in regulating ATPase activity of HSP70. In another hand, both R416 and R447 
residues are located in the SBD domain of HSP70, thus they may be the contacting 
residues between HSP70 and certain client peptides/proteins. Indeed, a recent paper 
showed that arginine 447 was important for the binding of HSP70 with superoxide 
dismutase 2 (SOD2), and this interaction regulated SOD2 antioxidant function in a stress-
inducible way (93). Whether methylation at these two arginine residues will affect the 
binding of HSP70 to its client proteins, particularly proteins that are involved in drug 
resistance, warrants further study. 
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CHAPTER 5 SUMMARY, DISCUSSION AND FUTURE DIRECTIONS 
5.1 SUMMARY 
5.1.1 Pro-tumorigenic role of PRMT1 in pancreatic cancer 
In this dissertation, I demonstrated that the level of PRMT1 expression was elevated in 
both human pancreatic tumor tissues and mutant Kras-induced mouse pancreatic tumors. 
Moreover, the IHC staining results from mouse model also revealed that the expression 
of PRMT1 protein was gradually elevated during pancreatic cancer progression, from low 
grade PanIN to high grade PanIN and finally PDAC. This observation also prompted an 
intriguing question that how PRMT1 expression is dysregulated during pancreatic 
carcinogenesis. My functional study further demonstrated a pro-tumorigenic function of 
PRMT1. Overexpression of PRMT1 promoted cancer cell proliferation, migration and 
invasion in vitro and xenograft tumor growth in vivo, while inhibiting PRMT1 expression by 
siRNA did the opposite. Besides, the effects of PRMT1 specific small molecular inhibitors 
were tested on both human and mouse pancreatic cancer cells. They could induce 
dramatic cell apoptosis in vitro and decrease tumor growth in vivo. In summary, many 
pieces of evidence in this dissertation suggest a pro-tumorigenic role of PRMT1 in 
pancreatic cancer pathogenesis and inhibition of PRMT1 expression and/or enzymatic 
activity can decrease pancreatic cancer growth. 
5.1.2 HSP70 protein is a novel methylation substrate of PRMT1 
In my study, I found that four major members of HSP70 protein family were interacting 
partners of PRMT1 in protein-protein interaction study. Due to the protein structure and 
sequence similarity among these proteins, it prompted me to study whether there is a 
conserved structure domain of these proteins that can interact with and be methylated by 
PRMT1. Using Co-IP assay, I demonstrated that at least four HSP70 family members, 
HSP70, HSC70, GRP75 and GRP78, could interact with PRMT1 in vitro. HSP70 was 
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selected as a representative protein for following studies. Further Co-IP and GST pull-
down assays with a series of HSP70 deletion mutants revealed amino acids 410-460 as 
a conserved interacting domain with PRMT1, and bioinformatics analysis indicated that 
there are three arginine residues that could be potential PRMT1 methylation sites. Then 
in vitro methylation assay was performed using synthesized peptides and recombinant 
proteins as substrates. Results showed that two conserved arginine residues, R416 and 
R447, of HSP70 were the primary PRMT1 methylation sites. The mass spectrometry 
analysis also confirmed the existence of protein arginine methylation in pancreatic cancer 
cells.   
5.1.3 Arginine methylation is essential for HSP70-mediated cell stress responses  
Since HSP70 is a critical protein involved in multiple cell stress responses, and 
chemotherapeutic drug resistance is a common problem in clinical practice, how arginine 
methylation influences HSP70 function in drug resistance is studied in my dissertation. 
Using HSP70 knock-out cell line, wildtype and methylation sites mutant HSP70 
recombinant proteins, my data demonstrated that arginine methylation at R416 and R447 
were essential for HSP70-mediated drug resistance to gemcitabine. Mutation of arginine 
to alanine at these positions prevented PRMT1-mediated methylation and therefore 
decreased cell drug resistance to gemcitabine both in vitro and in vivo. In contrast, 
reconstitution of wildtype HSP70 protein could rescue the drug resistance of HSP70 null 
cells. Meanwhile, the arginine methylation of HSP70 were also proved to be important for 
other types of environmental stress, like hydrogen peroxide induced oxidative stress.    
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5.2 DISCUSSION AND FUTURE DIRECTIONS 
5.2.1 Study the mechanisms underlying PRMT1 overexpression during pancreatic 
carcinogenesis 
My study demonstrated that PRMT1 protein is overexpressed in several gastrointestinal 
cancer types, such as pancreatic cancer, gastric cancer and colon cancer. Moreover, IHC 
staining results from mouse pancreatic cancer model also revealed that during pancreatic 
carcinogenesis, PRMT1 expression is gradually elevated. Therefore, how PRMT1 is 
overexpressed during this process is a question awaiting for answers. Analysis of TCGA 
data shows that copy number change and somatic mutations of PRMT1 gene are rarely 
detected in human tumor samples (data not shown), thus the transcriptional and/or post-
transcriptional regulation should be possible reasons for PRMT1 overexpression.  
First, the results from another study using pulmonary inflammation model showed that IL-
4 increased PRMT1 expression through STAT6 signaling in airway epithelial cells, while 
IL-1β up-regulated PRMT1 through NF-κB pathway in airway fibroblasts in lung (108). 
Similarly, in my preliminary study, I found that TNF-α treatment could induce PRMT1 
expression in several pancreatic cancer cell lines and 293T cells (data not shown). Since 
pancreatic cancer, including its pre-cancerous lesions, like PanIN, is usually associated 
with tissue inflammation, whether inflammatory molecules and inflammation signaling 
pathways play a role in PRMT1 up-regulation warrant further study.  
Second, during the stepwise progression of PanIN from low grade to high grade in stage 
1, 2, and 3, different genetic alterations are accumulated (1). KRAS mutations are 
detected in more than 90% of PanIN cases of all grades, and the average concentration 
of mutant KRAS alleles increase significantly with increasing grade of PanIN (109). In 
addition, the inactivation mutation of CDKN2A/p16, p53, and SMAD4 tumor suppressors 
is detected with increasing frequency in stage 2 and stage 3 lesions of PanIN (1). Thus 
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the increasing genetic alternations, particular KRAS mutation, can be a reason for 
increasing PRMT1 expression during pathogenesis. 
Third, other regulatory mechanisms, such as microRNA, could also be involved in PRMT1 
dysregulation. A recent study showed that in human hepatocellular carcinoma, miR-503 
suppressed cancer metastasis by targeting PRMT1 (71). Therefore the microRNA 
regulation is another research direction in my future study. 
5.2.2 Study how arginine methylation influences HSP70 chaperone function 
In my dissertation, I demonstrated that arginine methylation at R416 and R447 of HSP70 
were essential for its drug resistance function. However, how this is achieved at the 
molecular level and whether this is due to the alternation of HSP70 chaperone function is 
not clearly understood.  
As it is stated in Chapter 1 that addition of methyl group(s) to an arginine residue does not 
change the positive charge of this residue, but removes a potential hydrogen bond donor 
of this residue. The methylation sites R416 and R447 identified in my study are located in 
the substrate binding domain of HSP70.  Methylation of these residues may affect the 
binding affinity of HSP70 to certain client proteins and/or co-chaperone proteins, and 
therefore lead to the observed cell behavioral change under chemo drug treatment.  
For example, a recent study reported that the lysine acetylation at K77 of HSP70 promoted 
its binding to a co-chaperone Hop, and deacetylation at that site switched its binding 
preference to another co-chaperone CHIP (104). Whether the arginine methylation 
discovered in my study works in a similar way is to be addressed. Another research 
showed that glutamic acid 446 and arginine 447 of HSP70 were critical for the regulation 
of superoxide dismutase 2 (SOD2) antioxidant function (93). Considering my data proved 
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that arginine 447 was a methylation site of PRMT1, it is plausible that methylation at this 
specific position is important for the binding of HSP70 with SOD2.  
HSP70 protein has an ATPase enzyme activity, and ATP/ADP binding-induced 
conformational change is an important regulatory mechanism for HSP70 allosteric 
activation as a protein chaperone. Protein structure simulation and analysis in a recent 
study revealed that arginine 416 is located in the interface between the NBD and SBD of 
the ATP-bound conformation of HSP70 (104). Thus whether methylation at this amino 
acid residual will regulate the ATPase cycle of HSP70 needs further study.  
5.2.3 Study combined therapy of PRMT1 inhibitor and gemcitabine to treat 
pancreatic cancer. 
In this dissertation, I demonstrated the pro-tumorigenic function of PRMT1 in pancreatic 
cancer development, and that PRMT1-mediated arginine methylation was important for 
HSP70-mediated gemcitabine resistance. These observations provide at least two 
rationales to test combination use of PRMT1 inhibitor and gemcitabine to treat pancreatic 
cancer. First, inhibition of PRMT1 enzymatic activity itself can reduce tumor growth. This 
is not only proved in Chapter 2 of my dissertation, but also shown in another study using 
the same inhibitor (DB75) to reduce leukemia cell growth (69). Second, inhibition of 
PRMT1 activity can potentiate cytotoxicity of gemcitabine to cancer cells by reducing cell 
drug resistance. A recent study revealed that PRMT1-mediated Gli1 methylation promoted 
drug resistance function of Gli1 (110). This discovery, together with the function of HSP70 
methylation proved in my dissertation, suggests that PRMT1 plays a critical role in 
mediating chemo drug resistance, and therefore inhibition of PRMT1 in cancer cells may 
alleviate drug resistance. Furthermore, the PRMT1 specific inhibitor (DB75) used in my 
study, is originally developed and utilized for anti-parasite treatment by targeting the minor 
groove of AT-rich DNAs (111), thus the biological safety of this drug should not be a 
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concern in expanding its application to cancer therapy. One thing needs to be considered 
is the potential damage of this drug to normal pancreatic and other somatic cells. In my 
future study, I will study the tissue or cell selectivity of PRMT1 inhibitor to determine 
whether or not it only induces apoptosis of cancer cells rather than normal cells.  
5.2.4 Study the survival dependency on PRMT1 of pancreatic cancer cells 
In Chapter 4 of my dissertation, I showed that the PRMT1 knock-out MIA PaCa-2 
pancreatic cancer cells could not properly grow and proliferate. This observation is of great 
interest because it may indicate that pancreatic cancer cells have survival dependency on 
PRMT1. An early paper showed that PRMT1 null mouse embryos died at embryonic day 
6.5, but the embryonic stem (ES) cell lines established from PRMT1 null blastocysts were 
viable (112). Later on, another study revealed an essential role of PRMT1 in genome 
maintenance and cell proliferation using Cre-loxP mediated PRMT1 conditional knock-out 
mouse embryonic fibroblasts (MEFs) (29). Their data showed that loss of PRMT1 in MEFs 
leads to a higher incidence of chromosome losses, gains, structural rearrangements, and 
polyploidy, and finally resulted in cell death (29). This observation is similar to my data, 
thus I postulate that the extreme giant cells formed by PRMT1 null MIA PaCa-2 cells in 
my study may be a result of genome instability, aneuploidy and defect in cell division.  
During the preparation of this dissertation, a study published by Hsu et al. reported that 
Prmt1 is required for tumor initiation in p53/Rb-null osteosarcomas (OS) mouse model 
(113). Moreover, when Cre recombinase was induced in Prmt1flox/flox OS cells, those cells 
underwent Prmt1 inactivation and growth arrest in vitro (113). This observation also 
supports an essential role of PRMT1 in cancer cell growth and/or survival, although those 
authors used another cancer type that was different from pancreatic cancer in genetic 
background.  
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To study the physiological role of PRMT1 in pancreas development and pathogenesis, a 
pancreas specific PRMT1 conditional knock-out mouse model should be generated and 
utilized. Deletion of PRMT1 protein at different developmental stages can show the 
dependency of PRMT1 in normal pancreas development. When crossed with pancreas 
specific Kras mutant mouse line, the resultant mouse line can be used to study the role of 
PRMT1 in pancreatic cancer development. For example, it is interesting to assess whether 
deletion of PRMT1 in Kras mutation background can delay or even prevent PDAC initiation 
and development. 
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